DORI SABABLI KELIB CHIQADIGAN TOKSIK GEPATIT: ZAMONAVIY QARASHLAR.
Abstract
Izoh. Ushbu tadqiqotning maqsadi gepatotoksiklikka olib keladigan dorilarning yangilangan ro‘yxatini tayyorlash va ilmiy ma’lumotlarga ko‘ra, gepatotoksiklikka olib kelishi mumkin bo‘lgan dori-darmonlarni aniqlash. Gepatotoksik dorilarning ayrim jihatlari gepatotoksiklik, travma turi, gepatotoksiklik mexanizmlari, xavf omillari va klinik ko‘rinishlar kabilarda namoyon bo‘ldi. Gepatotoksiklik ehtimolini va lezyon turini baholash uchun uchta toifa belgilandi: aniq, ehtimoliy va mumkin bo‘lgan. Ro‘yxat gepatotoksikatsiyaga olib kelishi mumkin bo‘lgan 181 dori va 17 kombinatsiyalangan dozalash shakllari yoki terapevtik rejimlardan tuzilgan. Ulardan Metotreksat, Minotsiklin, Vankomitsin, Everolimus, Izoniazid va Tamoksifen ma’lum ehtimoliylar toifasiga kiritilgan. Xulosa: 180 dan ortiq gepatotoksik preparatlar aniqlandi, shulardan oltitasi ma’lum ehtimoliylar toifasiga, aksariyati mumkin bo‘lganlar toifasiga kiritilgan. Axborotni sarhisob qilsak, turli toifadagi dorilar jigar zaharlanishiga olib kelishi mumkin.
References
Foydalanilgan adabiyotlar.
1. Adams D., Ju C., Ramaiah S. et al. Mechanisms of immune-mediated liver injury // Toxicol Sci. – 2010. – Vol. 115, №2. – Р. 307–321.
2. Adriaenssens B., Roskams T., Steger P. et al. Hepatotoxicity related to itraconazole: report of three cases // Acta Clin. Belg. – 2001. – Vol. 56, №6. – Р. 364–369.
3. Amacher D. A toxicologist’s guide to biomarkers of hepatic response // Hum. Exp. Toxicol. – 2002. – Vol. 21, №5. – Р. 253–262.
4. Amariles P., Giraldo N., Faus M. Inter acciones medicamen-tosas: Aproximación para establecer y evaluar surelevancia clínica // Med. Clin. (Barc.). – 2007. – Vol. 129, №1. – Р. 27–35.
5. Andrade R., López-Ortega S. Hepatitis tóxicas // Rev. Española Enfermedades Dig. – 2006. – Vol. 98, №9. – Р. 701.
6. Bakke O., Manochia M., De Abajo F. et al. Drug safety dis-continuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective // Clin. Pharmacol. Ther. – 1995. – Vol. 58, №1. – Р. 108–117.
7. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting // J. Hepatol. – 1990. – Vol. 11, №2. – Р. 272-276
8. Björnsson E. Drug-induced liver injury: Hy’s rule revisited // Clin. Pharmacol. Ther. – 2006. – Vol. 79, №6. – Р. 521–528.
9. Brunt E. Nonalcoholic steatohepatiiis (NASH): further expansion of this clinical entity? // Liver. – 1999. – Vol. 19, №4. – Р. 263–264.
10. Castell J., Miñana M. Hepatitis induced aportóxicos. Mecanismos de toxicidad y patrones de lesión // GH Contin. – 2003. – Vol. 2, №5. – Р. 190–196.
11. Chen M., Borlak J., Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury // Hepatology. – 2013. – Vol. 58, №1. – Р. 388–396.
12. Chen Y., Yang X., Zeckel M. et al. Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis // Drug saf. – 2011. – Vol. 34, №1. – Р. 73–82.
13. Chien R., Yang L., Lin P. et al. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study // Hepatology. – 1997. – Vol. 25, №1. – Р. 103–107.
14. Cocozzella D., Curciarello J., Corallini O. et al. Propafenone hepatotoxicity: report of two new cases // Dig. Liver Dis. – 2003. – Vol. 48, №2. – Р. 354–357.
15. Clay K., Hanson J., Pope S. et al. Telithromycin: a pos-sible cause of severe liver damage? // Ann. Intern. Med. – 2006. – Vol. 144, №6. – Р. 142.
16. Edoute Y., Karmon Y., Roguin A. et al. Fatal liver necrosis associated with the use of nitrofurantoin // Isr. Med. Assoc. J. – 2001. – Vol. 3, №5. – Р. 382–383.
17. Fernández-Castañer A., García-Cortés M., Lucena M.et al. An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event // Rev. Esp. Enferm. Dig. – 2008. – Vol. 100, №5. – Р. 278–284.
18. Fisher K., Vuppalanchi R., Saxena R. Drug-induced liver injury // Arch Pathol Lab Med. – 2015. – Vol. 139, №7. – Р. 876–887.
19. Flaharty K., Chase S., Yaghsezian H., et al. Hepatotoxicity associated with amiodarone therapy // Pharmacotherapy. – 1989. – Vol. 9, №1. – Р. 39–44.
20. Fujimoto Y., Ohhira M., Miyokawa N. et al. Acarbose-induced hepatic injury // Lancet. – 1998. – Vol. 351 (9099). – Р. 340.
21. García-Cortés M., Andrade R., Lucena M. et al. Hepatotoxicidadsecundaria a fármacos de usocomún // Gastroenterol. Hepatol. – 2005. –Vol. 28, №8. – Р. 461–472.
22. Ghabril M., Fontana R., Rockey D. et al. Drug induced liver injury caused by intramuscular administered medications: the drug induced liver injury network (DILIN) experience // J. Clin. Gastroenterol. – 2013. – Vol. 47, №6. – Р. 553–558.
23. Gunawan B., Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity // Drug Metab. Rev. – 2004. – Vol. 36, №2. – Р. 301-312.
24. Hayashi P., Fontana R. Clinical features, diagnosis, and natural history of drug-induced liver injury // Semin. Liver. Dis. – 2014. – Vol. 34, №2. – Р. 134–144.
25. Hernández N., Bessone .F, Sánchez A. et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports // Ann. Hepatol. – 2014. – Vol. 13, №2. – Р. 231–239.
26. Hewitt M., Enoch S., Madden J. et al. Hepatotoxicity: a scheme for generating chemical categories for read-across, features, and exposure to drugs // J. Hepatol. – 2002. –Vol. 37, №5. – Р. 592–600.
27. Hydes T., Wright M., Jaynes E. et al. Nitrofurantoin immunemediated drug-induced liver injury: a serious complication of a commonly prescribed medication // Brit. Med. J. Case Rep. – 2014. – Vol. 2014.
28. Ibáñez L., Pérez E., Vidal X. et al. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical doubts // Wld J. Gastroenterol. – 2009. – Vol. 15, №39. – Р. 4865–4876.
29. Jacobson M., Hanks D., Ferrell L. Fatal acute hepatic necrosis due to fluconazole // Amer. J. Med. – 1994. – Vol. 96, №2. – Р. 188–190.
30. Jeserich M., Ihling C., Allgaier H. et al. Acute liver failure due to enalapril // Herz. – 2000. – Vol. 25, №7. – Р. 689–693. https://doi.org/10.1007/PL00001983
31. Jonas M., Eidson M. Propylthiouracil hepatotoxicity: two pediatric cases and review of literature // J. Pediatr. Gastroenterol. Nutr. – 1988. – Vol. 7, №5. – Р. 776–778.
32. Kaplowitz N. Drug-induced liver injury // Clin. Infect. Dis. – 2004. – Vol. 38 (Suppl 2). – Р. 44–48.
33. Kaplowitz N. Drug Induced – Hepatotoxicity // Ann. Intern. Med. – 1986. – Vol. 104, №6. – Р. 826–839.
34. Kass G., Price S. Role of mitochondria in drug-induced cholestatic injury // Clin. Liver. Dis. – 2008. – Vol. 12, №1. – Р. 27–51.
35. Kleiner D. The pathology of drug-induced liver injury // Semin. Liver. Dis. – 2009. – Vol. 29, №4. – Р. 364–372.
36. Koek G., Striker B., Blok A. et al. Flucloxacillin-associated hepatic iniurv // Liver. – 1994. – Vol. 14, №5. – Р. 225–229.
37. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies // Fund. Clin. Pharmacol. – 2008. – Vol. 22, №4. – Р. 335–353.
38. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver // Semin. Liver. Dis. – 2002. – Vol. 22, №2. – Р. 145–155.
39. Lawrenson R., Seaman H., Sundström A. et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data // Drug. Saf. – 2000. – Vol. 23, №4. – Р. 333–349.
40. Lee W. Drug-Induced Hepatotoxicity // New Engl. J. Med. – 2003. – Vol. 349, №5. – Р. 474–485.
41. Li H., Heller D., Leevy C. et al. Troglitazone-induced fulminant hepatitis. Report of a case with autopsy findings // J. Diab. Compl. – 2000. – Vol. 14, №3. – Р. 175–177.
42. Liss G., Lewis J. Drug-induced liver injury: what was new in 2008? // Exp. Opin. Drug. Metab.Toxicol. – 2009. – Vol. 5, №8. – Р. 843–860.
43. Lucena M., Andrade R., Rodrigo L. et al. Trovafloxacin-Induced Acute Hepatitis // Clin. Infect. Dis. – 2000. – Vol. 30, №2. – Р. 400–401.
44. Lucena M., Camargo R., Andrade R. et al. Comparison of two clinical scales for causality assessment in hepatotoxicity // Hepatology. – 2001. – Vol. 33, №1. – Р. 123–130.
45. Martí L., Olmo J., Tosca J. et al. Clinical evaluation of drug-induced hepatitis // Rev. Esp. Enfermedades Dig. – 2005. – Vol. 97, №4. – Р. 258–265.
46. Matic K., Mihaljevic P. Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report // Europ. J Psychiatry. – 2018. – Vol. 32, №4. – Р. 192–194.32
47. Melamud B., Lurie Y., Goldin E.et al. Methylprednisolone-induced liver injury: a diagnostic challenge // IMAJ. – 2014. – Vol. 16, №3. – Р. 180–181.
48. Navarro V., Senior J. Drug-related hepatotoxicity // New Engl. J. Med. – 2006. – Vol. 354, №7. – Р. 731–739. https://doi.org/10.1056/NEJMra052270
49. Pelli N., Setti M., Ceppa P. et al. Autoimmune hepatitis revealed by atorvastatin // Eurор. J. Gastroenterol. Hepatol. – 2003. – Vol. 15, №8. – Р. 921–924.
50. Pessayre D., Fromenty B., Berson A. et al. Central role of mitochondria in drug-induced liver injury // Drug. Metab. Rev. – 2012. – Vol. 44, №1. – Р. 34–87.
51. Pessayre D., Mansouri A., Berson A. et al. Mitochondrial involvement in drug-induced liver injury // Handb. Exp. Pharmacol. – 2010. – Vol. 196. – Р. 311–65. https://doi.org/10.1007/978-3-642-00663-0_11
52. Prince M., Burt A., Jones D. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis // Gut. – 2002. – Vol. 50, №3. – Р. 436–439.
53. Puppala A., Steinheber F. Fulminant hepatic failure associated with methyldopa // Amer. J. Gastroenterol. – 2017. – Vol. 68, №6. – Р. 578–581.
54. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease // J. Clin. Pathol. – 2009. – Vol. 62, №6. – Р. 481–492. https://doi.org/10.1136/jcp.2008.058248
55. Regev A., Seeff L., Merz M. et al. Causality assessment for suspected DILI during clinical phases of drug development // Drug. Saf. – 2014. – Vol. 37 (S1). – Р. 47–56.
56. Reuben A. Hy’s Law // Hepatology. – 2004. – Vol. 39, №2. – Р. 574–578. https://doi.org/10.1002/hep.20081
57. Schiano T.D., Bellary S.V., Cassidy M.J. et al. Subfulminantliver failure and severe hepatotoxicity caused by loratadineuse // Ann. Intern. Med. – 1996. – Vol. 125, №9. – Р. 738–740.
58. Sigro C., Clinard F., Ouazir K. et al. Incidence of drug-induced hepatic injuries: A French population-based study // Hepatology. – 2002. – Vol. 36, №2. – Р. 451–455.
59. Shepherd N., Dawson A., Crocker P. et al. Granular cells as a marker of early amiodarone hepatotoxicity: a pathological and analytical study // J. Clin. Pathol. – 1987. – Vol. 40, №4. – Р. 418–423. https://doi.org/10.1136/jcp.40.4.418
60. Stefan D., Hamilton J.P. Drug induced liver injury // US Gastroenterol. Hepatol. Rev. – 2010. –Vol. 6. – Р. 73–80.
61. Stolk M., Becx M., Kuypers K. et al. Severe hepatic side effects of ezetimibe // Clin. Gastroenterol. Hepatol. – 2006. – Vol. 4, №7. – Р. 908–911.
62. Tarantino G., Di Minno M., Capone D. Drug-induced liver injury: Is it somehow foreseeable? // Wld J. Gastroenterol. – 2009. – Vol. 15, №23. – Р. 2817–2833.
63. Tejada F. Hepatotoxicidadporfármacos // Rev. Сlín. Med. Fam. – 2010. – Vol. 3, №3. – Р. 177–191.
64. Thomas E., Rosenthal W., Zapiach L. et al. Spectrum of methyldopa liver injury // Amer. J. Gastroenterol. – 1977. – Vol. 68, №2. – Р. 125–133.
65. Van Parys G., Evenepoel C., Van Damme B. et al. Ketoconazole-induced hepatitis: a case with a definite structural alerts and insights into mechanism(s) of action // Crit. Rev. Toxicol. – 2013. – Vol. 43, №7. – Р. 537–558.
